Hypercholesterolemia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Hypercholesterolemia – Pipeline Review, H2 2017’, provides an overview of the Hypercholesterolemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypercholesterolemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia

The report reviews pipeline therapeutics for Hypercholesterolemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypercholesterolemia therapeutics and enlists all their major and minor projects

The report assesses Hypercholesterolemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypercholesterolemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AFFiRiS AG

Akcea Therapeutics Inc

ARMO Biosciences Inc

AstraZeneca Plc

BioLingus AG

Catabasis Pharmaceuticals Inc

Chong Kun Dang Pharmaceutical Corp

CymaBay Therapeutics Inc

Daewon Pharm Co Ltd

Daewoong Co Ltd

Dicerna Pharmaceuticals Inc

Dybly AG

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Golden Biotechnology Corp

Hanmi Pharmaceuticals Co Ltd

Immune Response BioPharma Inc

Kadmon Corp LLC

Kyorin Pharmaceutical Co Ltd

Leading BioSciences Inc

LipimetiX Development Inc

Lotus Pharmaceutical Co Ltd

Madrigal Pharmaceuticals Inc.

Medlab Clinical Ltd

Nanoform Cardiovascular Therapeutics Ltd

Noxopharm Ltd

Pfizer Inc

Progenra Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

Serometrix LLC

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

The Medicines Company

Viking Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Hypercholesterolemia - Overview 6

Hypercholesterolemia - Therapeutics Development 7

Hypercholesterolemia - Therapeutics Assessment 19

Hypercholesterolemia - Companies Involved in Therapeutics Development 29

Hypercholesterolemia - Drug Profiles 45

Hypercholesterolemia - Dormant Projects 180

Hypercholesterolemia - Discontinued Products 184

Hypercholesterolemia - Product Development Milestones 186

Appendix 201

List of Tables

List of Tables

Number of Products under Development for Hypercholesterolemia, H2 2017 14

Number of Products under Development by Companies, H2 2017 16

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Number of Products under Development by Universities/Institutes, H2 2017 19

Products under Development by Companies, H2 2017 20

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 21

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 22

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 23

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 24

Products under Development by Universities/Institutes, H2 2017 25

Number of Products by Stage and Target, H2 2017 27

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 28

Number of Products by Stage and Mechanism of Action, H2 2017 30

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 31

Number of Products by Stage and Route of Administration, H2 2017 33

Number of Products by Stage and Molecule Type, H2 2017 35

Hypercholesterolemia – Pipeline by AFFiRiS AG, H2 2017 36

Hypercholesterolemia – Pipeline by Akcea Therapeutics Inc, H2 2017 36

Hypercholesterolemia – Pipeline by ARMO Biosciences Inc, H2 2017 37

Hypercholesterolemia – Pipeline by AstraZeneca Plc, H2 2017 37

Hypercholesterolemia – Pipeline by BioLingus AG, H2 2017 38

Hypercholesterolemia – Pipeline by Catabasis Pharmaceuticals Inc, H2 2017 38

Hypercholesterolemia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 39

Hypercholesterolemia – Pipeline by CymaBay Therapeutics Inc, H2 2017 39

Hypercholesterolemia – Pipeline by Daewon Pharm Co Ltd, H2 2017 40

Hypercholesterolemia – Pipeline by Daewoong Co Ltd, H2 2017 40

Hypercholesterolemia – Pipeline by Dicerna Pharmaceuticals Inc, H2 2017 41

Hypercholesterolemia – Pipeline by Dybly AG, H2 2017 41

Hypercholesterolemia – Pipeline by Esperion Therapeutics Inc, H2 2017 41

Hypercholesterolemia – Pipeline by Gemphire Therapeutics Inc, H2 2017 42

Hypercholesterolemia – Pipeline by Golden Biotechnology Corp, H2 2017 43

Hypercholesterolemia – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 43

Hypercholesterolemia – Pipeline by Immune Response BioPharma Inc, H2 2017 43

Hypercholesterolemia – Pipeline by Kadmon Corp LLC, H2 2017 44

Hypercholesterolemia – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 44

Hypercholesterolemia – Pipeline by Leading BioSciences Inc, H2 2017 44

Hypercholesterolemia – Pipeline by LipimetiX Development Inc, H2 2017 45

Hypercholesterolemia – Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017 45

Hypercholesterolemia – Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 46

Hypercholesterolemia – Pipeline by Medlab Clinical Ltd, H2 2017 46

Hypercholesterolemia – Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017 47

Hypercholesterolemia – Pipeline by Noxopharm Ltd, H2 2017 47

Hypercholesterolemia – Pipeline by Pfizer Inc, H2 2017 47

Hypercholesterolemia – Pipeline by Progenra Inc, H2 2017 48

Hypercholesterolemia – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 48

Hypercholesterolemia – Pipeline by RegenxBio Inc, H2 2017 49

Hypercholesterolemia – Pipeline by Serometrix LLC, H2 2017 49

Hypercholesterolemia – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017 50

Hypercholesterolemia – Pipeline by The Medicines Company, H2 2017 50

Hypercholesterolemia – Pipeline by Viking Therapeutics Inc, H2 2017 51

Hypercholesterolemia – Dormant Projects, H2 2017 187

Hypercholesterolemia – Dormant Projects, H2 2017 (Contd..1), H2 2017 188

Hypercholesterolemia – Dormant Projects, H2 2017 (Contd..2), H2 2017 189

Hypercholesterolemia – Dormant Projects, H2 2017 (Contd..3), H2 2017 190

Hypercholesterolemia – Discontinued Products, H2 2017 191

Hypercholesterolemia – Discontinued Products, H2 2017 (Contd..1), H2 2017 192

List of Figures

List of Figures

Number of Products under Development for Hypercholesterolemia, H2 2017 14

Number of Products under Development by Companies, H2 2017 15

Number of Products under Development by Universities/Institutes, H2 2017 19

Number of Products by Top 10 Targets, H2 2017 26

Number of Products by Stage and Top 10 Targets, H2 2017 26

Number of Products by Top 10 Mechanism of Actions, H2 2017 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 29

Number of Products by Routes of Administration, H2 2017 32

Number of Products by Stage and Routes of Administration, H2 2017 32

Number of Products by Molecule Types, H2 2017 34

Number of Products by Stage and Molecule Types, H2 2017 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports